Webinar: ๐ ๐ซ๐จ๐ฆ ๐๐๐ญ๐ ๐ญ๐จ ๐๐ข๐ฌ๐๐จ๐ฏ๐๐ซ๐ฒ: ๐๐๐ฏ๐๐ซ๐๐ ๐ข๐ง๐ ๐๐ฒ๐ฌ๐ญ๐๐ฆ๐ฌ ๐๐ข๐จ๐ฅ๐จ๐ ๐ฒ ๐๐ง๐ ๐๐ ๐ญ๐จ ๐๐๐๐๐ฅ๐๐ซ๐๐ญ๐ ๐๐ซ๐๐ง๐ฌ๐ฅ๐๐ญ๐ข๐จ๐ง๐๐ฅ ๐๐๐๐ข๐๐ข๐ง๐
๐
๐๐ฎ๐๐ฒ: November 4, 2026 โ 17.00 – 18.00 EET (Online)
๐ ๐ฅ๐ฒ๐ด๐ถ๐๐๐ฟ๐ฎ๐๐ถ๐ผ๐ป: https://lnkd.in/dvg6y4Xr.
In this webinar, we will explore how modern systems biology and AI can โ and cannot โ realistically contribute to the biopharmaceutical industry, from target discovery all the way through Phase IV, and what could meaningfully improve the odds of translational success.
Darya Orlova is the Chief Scientific Officer at Intercellular Inc., with extensive experience building production computational platforms and leading cross-functional research teams at organizations including Genentech, Cell Signaling Technology, and Stanford University. She also co-founded Couloir Bio, which was acquired by Intercellular, and joined as CSO to lead the combined company’s scientific vision.
Best regards,
Janina Stauffer
